The Confluence of Innovation in Therapeutics and Regulation: Recent CMC Considerations

The field of human therapeutics has expanded tremendously from small molecules to complex biological modalities, and this trend has accelerated in the last two decades with a greater diversity in the types and applications of novel modalities, accompanied by increasing sophistication in drug deliver...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2020-12, Vol.109 (12), p.3524-3534
Main Authors: Gutierrez, Lucas, Cauchon, Nina S., Christian, Twinkle R., Giffin, Michael J., Abernathy, Michael J.
Format: Article
Language:English
Subjects:
Antibody drug(s)
Automation
Drug Delivery Systems
Drug design
Gene therapy
Humans
Immunotherapy
Liposome
Liposomes
Nanoparticle(s)
Nanoparticles
Printing, Three-Dimensional
Regulatory science
Review
Targeted drug delivery
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The field of human therapeutics has expanded tremendously from small molecules to complex biological modalities, and this trend has accelerated in the last two decades with a greater diversity in the types and applications of novel modalities, accompanied by increasing sophistication in drug delivery technology. These innovations have led to a corresponding increase in the number of therapies seeking regulatory approval, and as the industry continues to evolve regulations will need to adapt to the ever-changing landscape. The growth in this field thus represents a challenge for regulatory authorities as well as for sponsors. This review provides a brief description of novel biologics, including innovative antibody therapeutics, genetic modification technologies, new developments in vaccines, and multifunctional modalities. It also describes a few pertinent drug delivery mechanisms such as nanoparticles, liposomes, coformulation, recombinant human hyaluronidase for subcutaneous delivery, pulmonary delivery, and 3D printing. In addition, it provides an overview of the current CMC regulatory challenges and discusses potential methods of accelerating regulatory mechanisms for more efficient approvals. Finally, we look at the future of biotherapeutics and emphasize the need to bring these modalities to the forefront of patient care from a global perspective as effectively as possible.
ISSN:0022-3549
1520-6017
DOI:10.1016/j.xphs.2020.09.025